Aethir's "financial maneuvering": after raising 4.35 billion, they plan to spend 45 million to buy their own coin.

This wave has something to offer. Aethir co-founder announces that its asset reserve institution Predictive Oncology has officially logged in to NASDAQ (NASDAQ: POAI), and in the next 45 days, it plans to repurchase $45 million worth of ATH Tokens from the Secondary Market.

The background is as follows: POAI has just completed a PIPE financing of $343.5 million, and is now directly using this money to support the treasury strategy of ATH. In simple terms - the USD raised is directly exchanged for its own coin, forming a positive cycle.

Data Comparison:

• Current ATH Price: $0.0162 (-15.22%)
• 45 million USD buyback, at the current price it can absorb a lot of chips
• This operation is equivalent to providing “mechanical support” to ATH.

How to understand: This is a typical tactic of listed companies to support their stock prices - the institutional funds raised are directly used for market intervention, stabilizing the coin price while achieving diversification of asset reserves. This is similar to the logic of Microstrategy hoarding BTC like crazy last year.

However, the risk points must be clearly understood: the ATH has already seen a significant decline this year, and whether the buyback can reverse market sentiment will depend on the subsequent ecological development. Simply relying on financial operations cannot sustain for too long.